
Daniela Strobbe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8617527/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pyroptosis targeting via mitochondria: An educated guess to innovate COVIDâ€19 therapies. British Journal of Pharmacology, 2022, 179, 2081-2085.	2.7	3
2	The role of mtDNA haplogroups on metabolic features in narcolepsy type 1. Mitochondrion, 2022, 63, 37-42.	1.6	3
3	NHâ€sulfoximine: A novel pharmacological inhibitor of the mitochondrial F ₁ F _o â€ATPase, which suppresses viability of cancerous cells. British Journal of Pharmacology, 2021, 178, 298-311.	2.7	6
4	The ATPase Inhibitory Factor 1 (IF1) regulates the expression of the mitochondrial Ca2+ uniporter (MCU) via the AMPK/CREB pathway. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, 1868, 118860.	1.9	9
5	Links between mitochondrial retrograde response and mitophagy in pathogenic cell signalling. Cellular and Molecular Life Sciences, 2021, 78, 3767-3775.	2.4	8
6	Pharmacological advances in mitochondrial therapy. EBioMedicine, 2021, 65, 103244.	2.7	54
7	The translocator protein (TSPO) is prodromal to mitophagy loss in neurotoxicity. Molecular Psychiatry, 2021, 26, 2721-2739.	4.1	10
8	Speciesâ€specific consequences of an E40K missense mutation in superoxide dismutase 1 (SOD1). FASEB Journal, 2020, 34, 458-473.	0.2	5
9	Mitochondria Regulate Inflammatory Paracrine Signalling in Neurodegeneration. Journal of NeuroImmune Pharmacology, 2020, 15, 565-566.	2.1	1
10	Mitochondria form contact sites with the nucleus to couple prosurvival retrograde response. Science Advances, 2020, 6, .	4.7	79
11	Targeting Drp1 and mitochondrial fission for therapeutic immune modulation. Pharmacological Research, 2019, 146, 104317.	3.1	35
12	Exploring mitochondrial cholesterol signalling for therapeutic intervention in neurological conditions. British Journal of Pharmacology, 2019, 176, 4284-4292.	2.7	7
13	Mitochondrial pharmacology: featured mechanisms and approaches for therapy translation. British Journal of Pharmacology, 2019, 176, 4245-4246.	2.7	2
14	Haplogroup J mitogenomes are the most sensitive to the pesticide rotenone: Relevance for human diseases. Neurobiology of Disease, 2018, 114, 129-139.	2.1	22
15	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	5.0	4,036
16	Anxiolytic Therapy: A Paradigm of Successful Mitochondrial Pharmacology. Trends in Pharmacological Sciences, 2018, 39, 437-439.	4.0	12
17	Transglutaminase Type 2 Regulates ER-Mitochondria Contact Sites by Interacting with GRP75. Cell Reports, 2018, 25, 3573-3581.e4.	2.9	101
18	Common Traits Spark the Mitophagy/Xenophagy Interplay. Frontiers in Physiology, 2018, 9, 1172.	1.3	13

#	Article	IF	CITATIONS
19	HUWE1 E3 ligase promotes PINK1/PARKIN-independent mitophagy by regulating AMBRA1 activation via IKKα. Nature Communications, 2018, 9, 3755.	5.8	198
20	MitoCPR: Meticulous Monitoring of Mitochondrial Proteostasis. Molecular Cell, 2018, 71, 8-9.	4.5	8
21	Distinct Mechanisms of Pathogenic DJ-1 Mutations in Mitochondrial Quality Control. Frontiers in Molecular Neuroscience, 2018, 11, 68.	1.4	25
22	Reduction of the ATPase inhibitory factor 1 (IF1) leads to visual impairment in vertebrates. Cell Death and Disease, 2018, 9, 669.	2.7	15
23	Breast cancer cells exploit mitophagy to exert therapy resistance. Oncotarget, 2018, 9, 14040-14041.	0.8	6
24	The pharmacological regulation of cellular mitophagy. Nature Chemical Biology, 2017, 13, 136-146.	3.9	240
25	Control of Mitochondrial Remodeling by the ATPase Inhibitory Factor 1ÂUnveils a Pro-survival Relay via OPA1. Cell Reports, 2017, 18, 1869-1883.	2.9	66
26	The 18 kDa Translocator Protein (TSPO): Cholesterol Trafficking and the Biology of a Prognostic and Therapeutic Mitochondrial Target. Biological and Medical Physics Series, 2017, , 285-315.	0.3	2
27	Molecular Biology Digest of Cell Mitophagy. International Review of Cell and Molecular Biology, 2017, 332, 233-258.	1.6	10
28	A role for TSPO in mitochondrial Ca2+ homeostasis and redox stress signaling. Cell Death and Disease, 2017, 8, e2896-e2896.	2.7	75
29	Human Amniocytes Are Receptive to Chemically Induced Reprogramming to Pluripotency. Molecular Therapy, 2017, 25, 427-442.	3.7	10
30	Dysregulated mitophagy and mitochondrial organization in optic atrophy due to <i>OPA1</i> mutations. Neurology, 2017, 88, 131-142.	1.5	81
31	Reversible Keap1 inhibitors are preferential pharmacological tools to modulate cellular mitophagy. Scientific Reports, 2017, 7, 10303.	1.6	42
32	Clinical Features and Complications of the HLA-B27-associated Acute Anterior Uveitis: A Metanalysis. Seminars in Ophthalmology, 2017, 32, 689-701.	0.8	49
33	Circulating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index. PLoS ONE, 2017, 12, e0169454.	1.1	32
34	Tumor suppressive Ca2+ signaling is driven by IP3 receptor fitness. Cell Stress, 2017, 1, 73-78.	1.4	14
35	Mitophagy and the therapeutic clearance of damaged mitochondria for neuroprotection. International Journal of Biochemistry and Cell Biology, 2016, 79, 382-387.	1.2	36
36	TSPO drives post-translational modifications of the VDAC regulating mitochondrial signaling and quality control mechanisms. Biochimica Et Biophysica Acta - Bioenergetics, 2016, 1857, e65.	0.5	0

#	Article	IF	CITATIONS
37	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
38	Mitochondrial pharmacology: A need in modern biomedicine. Pharmacological Research, 2016, 103, 204-205.	3.1	0
39	TSPO: kaleidoscopic 18-kDa amid biochemical pharmacology, control and targeting of mitochondria. Biochemical Journal, 2016, 473, 107-121.	1.7	67
40	Neuroprotective coordination of cell mitophagy by the ATPase Inhibitory Factor 1. Pharmacological Research, 2016, 103, 56-68.	3.1	23
41	TSPO is a REDOX regulator of cell mitophagy. Biochemical Society Transactions, 2015, 43, 543-552.	1.6	53
42	TSPO: functions and applications of a mitochondrial stress response pathway. Biochemical Society Transactions, 2015, 43, 593-594.	1.6	7
43	The transglutaminase type 2 and pyruvate kinase isoenzyme M2 interplay in autophagy regulation. Oncotarget, 2015, 6, 44941-44954.	0.8	24
44	TSPO the unrested: challenged opinions of a resourceful mitochondrial protein. Trends in Endocrinology and Metabolism, 2015, 26, 333-334.	3.1	4
45	New Zebrafish Models of Neurodegeneration. Current Neurology and Neuroscience Reports, 2015, 15, 33.	2.0	32
46	Controlled and Impaired Mitochondrial Quality in Neurons: Molecular Physiology and Prospective Pharmacology. Pharmacological Research, 2015, 99, 410-424.	3.1	20
47	The shrimp mitochondrial FoF1-ATPase inhibitory factor 1 (IF1). Journal of Bioenergetics and Biomembranes, 2015, 47, 383-393.	1.0	5
48	AMBRA1 is able to induce mitophagy via LC3 binding, regardless of PARKIN and p62/SQSTM1. Cell Death and Differentiation, 2015, 22, 419-432.	5.0	294
49	Transglutaminase 2 ablation leads to mitophagy impairment associated with a metabolic shift towards aerobic glycolysis. Cell Death and Differentiation, 2015, 22, 408-418.	5.0	48
50	Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death and Differentiation, 2015, 22, 58-73.	5.0	811
51	Reconsidering the Lecture in Modern Veterinary Education. Journal of Veterinary Medical Education, 2014, 41, 138-145.	0.4	8
52	TSPO interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control. Autophagy, 2014, 10, 2279-2296.	4.3	174
53	Culturing muscle fibres in hanging drop: A novel approach to solve an old problem. Biology of the Cell, 2014, 106, 72-82.	0.7	8
54	The compound <scp>BTB</scp> 06584 is an <scp>IF</scp> ₁ â€dependent selective inhibitor of the mitochondrial <scp>F</scp> ₁ <scp>F</scp> oâ€ <scp>ATP</scp> ase. British Journal of Pharmacology, 2014, 171, 4193-4206.	2.7	30

#	Article	IF	CITATIONS
55	PMI: A ΔÎ [°] m Independent Pharmacological Regulator of Mitophagy. Chemistry and Biology, 2014, 21, 1585-1596.	6.2	125
56	AD-linked, toxic NH2 human tau affects the quality control of mitochondria in neurons. Neurobiology of Disease, 2014, 62, 489-507.	2.1	62
57	Peptide Targeting of Mitochondria Elicits Testosterone Formation. Molecular Therapy, 2014, 22, 1727-1729.	3.7	4
58	Type 2 Transglutaminase, mitochondria and Huntington's disease: Menage a trois. Mitochondrion, 2014, 19, 97-104.	1.6	18
59	Cell metabolism sets the differences between subpopulations of satellite cells (SCs). BMC Cell Biology, 2013, 14, 24.	3.0	6
60	Treatment of corneal neovascularization in ocular chemical injury with an off-label use of subconjunctival bevacizumab: a case report. Journal of Medical Case Reports, 2013, 7, 199.	0.4	3
61	Genome-wide RNAi screen identifies ATPase inhibitory factor 1 (ATPIF1) as essential for PARK2 recruitment and mitophagy. Autophagy, 2013, 9, 1770-1779.	4.3	70
62	The novel <scp>NOX</scp> inhibitor 2â€acetylphenothiazine impairs collagenâ€dependent thrombus formation in a <scp>GPVI</scp> â€dependent manner. British Journal of Pharmacology, 2013, 168, 212-224.	2.7	64
63	The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene, 2013, 32, 699-712.	2.6	224
64	Ca ²⁺ in quality control. Autophagy, 2013, 9, 1710-1719.	4.3	88
65	IF1 limits the apoptotic-signalling cascade by preventing mitochondrial remodelling. Cell Death and Differentiation, 2013, 20, 686-697.	5.0	83
66	Mitochondrial IF ₁ preserves cristae structure to limit apoptotic cell death signaling. Cell Cycle, 2013, 12, 2530-2532.	1.3	15
67	Keeping the engine clean. Autophagy, 2013, 9, 1647-1647.	4.3	8
68	Effects of Intravitreal Bevacizumab on Inflammatory Choroidal Neovascular Membrane. European Journal of Ophthalmology, 2013, 23, 114-118.	0.7	12
69	Autocrine amplification of integrin αIIbβ3 activation and platelet adhesive responses by deoxyribose-1-phosphate. Thrombosis and Haemostasis, 2013, 109, 1108-1119.	1.8	9
70	Regulation of Mitochondrial Morphogenesis by Annexin A6. PLoS ONE, 2013, 8, e53774.	1.1	53
71	HtrA2 deficiency causes mitochondrial uncoupling through the F1F0-ATP synthase and consequent ATP depletion. Cell Death and Disease, 2012, 3, e335-e335.	2.7	32
72	Molecular Regulation of the Mitochondrial F _{1} F _{o} -ATPsynthase: Physiological and Pathological Significance of the Inhibitory Factor 1 (IF ₁). International Journal of Cell Biology, 2012, 2012, 1-12.	1.0	52

#	Article	IF	CITATIONS
73	Editorial [Hot Topic: The Physiology and Pharmacology of the Mitochondrial 18 kDa Translocator Protein (TSPO): An Emerging Molecular Target for Diagnosis and Therapy (Guest Editor: Michelangelo) Tj ETQq1	1 00778843	14 œBT /Ove
74	Mitochondrial Atpif1 regulates haem synthesis in developing erythroblasts. Nature, 2012, 491, 608-612.	13.7	78
75	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
76	PK11195 Inhibits Mitophagy Targeting the F1Fo-ATPsynthase in Bcl-2 Knock-Down Cells. Current Molecular Medicine, 2012, 12, 476-482.	0.6	20
77	Role of the Intravitreal Growth Factors in the Pathogenesis of Idiopathic Epiretinal Membrane. , 2011, 52, 5786.		50
78	Ca ²⁺ -dependent autophagy is enhanced by the pharmacological agent PK11195. Autophagy, 2010, 6, 607-613.	4.3	25
79	Paracrine Stimulation of Endothelial Cell Motility and Angiogenesis by Platelet-Derived Deoxyribose-1-Phosphate. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2631-2638.	1.1	16
80	Albumin Uptake in OK Cells Exposed to Rotenone: A Model for Studying the Effects of Mitochondrial Dysfunction on Endocytosis in the Proximal Tubule?. Nephron Physiology, 2010, 115, p9-p19.	1.5	5
81	Functional and structural alterations in the endoplasmic reticulum and mitochondria during apoptosis triggered by C2-ceramide and CD95/APO-1/FAS receptor stimulation. Biochemical and Biophysical Research Communications, 2010, 391, 575-581.	1.0	17
82	Clonal Characterization of Rat Muscle Satellite Cells: Proliferation, Metabolism and Differentiation Define an Intrinsic Heterogeneity. PLoS ONE, 2010, 5, e8523.	1.1	66
83	Inorganic Polyphosphate and Energy Metabolism in Mammalian Cells. Journal of Biological Chemistry, 2010, 285, 9420-9428.	1.6	161
84	IF1: setting the pace of the F1Fo-ATP synthase. Trends in Biochemical Sciences, 2009, 34, 343-350.	3.7	120
85	IF1, the endogenous regulator of the F1Fo-ATPsynthase, defines mitochondrial volume fraction in HeLa cells by regulating autophagy. Biochimica Et Biophysica Acta - Bioenergetics, 2009, 1787, 393-401.	0.5	58
86	Modulation of intracellular Ca2+ signalling in HeLa cells by the apoptotic cell death enhancer PK11195. Biochemical Pharmacology, 2008, 76, 1628-1636.	2.0	24
87	Regulation of Mitochondrial Structure and Function by the F1Fo-ATPase Inhibitor Protein, IF1. Cell Metabolism, 2008, 8, 13-25.	7.2	246
88	Mitochondrial ND5 Gene Variation Associated with Encephalomyopathy and Mitochondrial ATP Consumption. Journal of Biological Chemistry, 2007, 282, 36845-36852.	1.6	59
89	Control of Macroautophagy by Calcium, Calmodulin-Dependent Kinase Kinase-β, and Bcl-2. Molecular Cell, 2007, 25, 193-205.	4.5	961
90	Bcl-2 and Bax Exert Opposing Effects on Ca2+ Signaling, Which Do Not Depend on Their Putative Pore-forming Region. Journal of Biological Chemistry, 2004, 279, 54581-54589.	1.6	98

#	Article	IF	CITATIONS
91	The Coxsackievirus 2B Protein Suppresses Apoptotic Host Cell Responses by Manipulating Intracellular Ca2+ Homeostasis. Journal of Biological Chemistry, 2004, 279, 18440-18450.	1.6	116
92	Mitochondrial Ca2+ homeostasis in health and disease. Biological Research, 2004, 37, 653-60.	1.5	46
93	Expression of polycystin-1 C-terminal fragment enhances the ATP-induced Ca2+ release in human kidney cells. Biochemical and Biophysical Research Communications, 2003, 301, 657-664.	1.0	24
94	Endoplasmic reticulum, Bcl-2 and Ca2+ handling in apoptosis. Cell Calcium, 2002, 32, 413-420.	1.1	97